160 related articles for article (PubMed ID: 31379366)
21. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.
Kwakman JJM; Vink G; Vestjens JH; Beerepoot LV; de Groot JW; Jansen RL; Opdam FL; Boot H; Creemers GJ; van Rooijen JM; Los M; Vulink AJE; Schut H; van Meerten E; Baars A; Hamberg P; Kapiteijn E; Sommeijer DW; Punt CJA; Koopman M
Int J Clin Oncol; 2018 Jun; 23(3):482-489. PubMed ID: 29204933
[TBL] [Abstract][Full Text] [Related]
22. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Chan BM; Hochster HS; Lenz HJ
Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
[TBL] [Abstract][Full Text] [Related]
23. [Safety and Efficacy of TAS-102 with Bevacizumab for the Treatment of Unresectable Metastatic Colorectal Cancer - A Case Report].
Arakawa S; Horiguchi A; Tomishige H; Kawabe N; Nagata H; Ishihara S; Ito M; Asano Y; Ito R; Isetani M; Shimizu K; Kamio K; Kawai T; Yasuoka H; Imaeda Y
Gan To Kagaku Ryoho; 2018 Apr; 45(4):649-651. PubMed ID: 29650823
[TBL] [Abstract][Full Text] [Related]
24. Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors.
Uboha NV; Lubner SJ; LoConte NK; Mulkerin DL; Eickhoff JC; Deming DA
Invest New Drugs; 2020 Oct; 38(5):1520-1525. PubMed ID: 32253554
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
Sueda T; Sakai D; Kudo T; Sugiura T; Takahashi H; Haraguchi N; Nishimura J; Hata T; Hayashi T; Mizushima T; Doki Y; Mori M; Satoh T
Anticancer Res; 2016 Aug; 36(8):4299-306. PubMed ID: 27466548
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer.
Doi T; Yoshino T; Fuse N; Boku N; Yamazaki K; Koizumi W; Shimada K; Takinishi Y; Ohtsu A
Invest New Drugs; 2015 Oct; 33(5):1068-77. PubMed ID: 26163340
[TBL] [Abstract][Full Text] [Related]
27. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors.
Overman MJ; Kopetz S; Varadhachary G; Fukushima M; Kuwata K; Mita A; Wolff RA; Hoff P; Xiong H; Abbruzzese JL
Cancer Invest; 2008 Oct; 26(8):794-9. PubMed ID: 18798063
[TBL] [Abstract][Full Text] [Related]
28. Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
Yoshino T; Kojima T; Bando H; Yamazaki T; Naito Y; Mukai H; Fuse N; Goto K; Ito Y; Doi T; Ohtsu A
Cancer Sci; 2016 May; 107(5):659-65. PubMed ID: 26918279
[TBL] [Abstract][Full Text] [Related]
29. FDA Approval Summary: TAS-102.
Marcus L; Lemery SJ; Khasar S; Wearne E; Helms WS; Yuan W; He K; Cao X; Yu J; Zhao H; Wang Y; Stephens O; Englund E; Agarwal R; Keegan P; Pazdur R
Clin Cancer Res; 2017 Jun; 23(12):2924-2927. PubMed ID: 28213365
[TBL] [Abstract][Full Text] [Related]
30. Safety and Efficacy of Trifluridine-Tipiracil Hydrochloride Oral Combination (TAS-102) in Patients with Unresectable Colorectal Cancer.
Narihiro S; Suwa K; Ushigome T; Ohtsu M; Ryu S; Shimoyama Y; Okamoto T; Yanaga K
In Vivo; 2018; 32(6):1643-1646. PubMed ID: 30348728
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer.
Arita S; Shirakawa T; Matsushita Y; Shimokawa HK; Hirano G; Makiyama A; Shibata Y; Tamura S; Esaki T; Mitsugi K; Ariyama H; Kusaba H; Akashi K; Baba E
Anticancer Res; 2016 Apr; 36(4):1959-66. PubMed ID: 27069187
[TBL] [Abstract][Full Text] [Related]
32. Regorafenib-to-trifluridine/tipiracil Versus the Reverse Sequence for Refractory Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Real-life Experience.
Signorelli C; Gemma D; Grande R; DE Marco S; Saltarelli R; Morandi MG; Spinelli GP; Zoratto F; Sperduti I; Chilelli MG; Ceribelli A; Ruggeri EM
Anticancer Res; 2021 May; 41(5):2553-2561. PubMed ID: 33952483
[TBL] [Abstract][Full Text] [Related]
33. Analysis of neutropenia as a predictive factor of the efficacy of trifluridine-tipiracil treatment.
Domínguez Senín L; Rodriguez Garcés MY; Aviñó Tarazona V; Amor Urbano M; Santos-Rubio MD; Bayo Calero J
Int J Clin Pharmacol Ther; 2023 Aug; 61(8):346-353. PubMed ID: 37288835
[TBL] [Abstract][Full Text] [Related]
34. A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment.
Saif MW; Becerra CR; Fakih MG; Sun W; Popovic L; Krishnamurthi S; George TJ; Rudek MA; Shepard DR; Skopek J; Sramek V; Zaric B; Yamamiya I; Benhadji KA; Hamada K; He Y; Rosen L
Cancer Chemother Pharmacol; 2021 Sep; 88(3):485-497. PubMed ID: 34097100
[TBL] [Abstract][Full Text] [Related]
35. TAS-102 for metastatic refractory colorectal cancer.
Cleghorn S
Lancet Oncol; 2015 Jul; 16(7):e314. PubMed ID: 26004375
[No Abstract] [Full Text] [Related]
36. Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status.
Carriles C; Jimenez-Fonseca P; Sánchez-Cánovas M; Pimentel P; Carmona-Bayonas A; García T; Carbajales-Álvarez M; Lozano-Blázquez A
Clin Transl Oncol; 2019 Dec; 21(12):1781-1785. PubMed ID: 31209792
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram.
Fernandez Montes A; Vazquez Rivera F; Martinez Lago N; Covela Rúa M; Cousillas Castiñeiras A; Gonzalez Villarroel P; de la Cámara Gómez J; Méndez Méndez JC; Salgado Fernández M; Candamio Folgar S; Reboredo López M; Carmona Campos M; Gallardo Martín E; Jorge Fernández M; Pellón Augusto ML; París Bouzas L; García Gómez J
Clin Transl Oncol; 2020 Mar; 22(3):351-359. PubMed ID: 31073972
[TBL] [Abstract][Full Text] [Related]
38. Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102.
Bekir Hacioglu M; Kostek O; Kurt N; Kucukarda A; Gokyer A; Ustabasioglu FE; Karatas F; Tuncbilek N; Uzunoglu S; Bilici A; Cicin I; Erdogan B
J BUON; 2019; 24(5):2198-2204. PubMed ID: 31786894
[TBL] [Abstract][Full Text] [Related]
39. Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment.
Saif MW; Rosen L; Rudek MA; Sun W; Shepard DR; Becerra C; Yamashita F; Bebeau P; Winkler R
Br J Clin Pharmacol; 2019 Jun; 85(6):1239-1246. PubMed ID: 30628113
[TBL] [Abstract][Full Text] [Related]
40. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.
Overman MJ; Varadhachary G; Kopetz S; Thomas MB; Fukushima M; Kuwata K; Mita A; Wolff RA; Hoff PM; Xiong H; Abbruzzese JL
Invest New Drugs; 2008 Oct; 26(5):445-54. PubMed ID: 18528634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
